RU2131248C1 - Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих - Google Patents

Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих Download PDF

Info

Publication number
RU2131248C1
RU2131248C1 RU93045145A RU93045145A RU2131248C1 RU 2131248 C1 RU2131248 C1 RU 2131248C1 RU 93045145 A RU93045145 A RU 93045145A RU 93045145 A RU93045145 A RU 93045145A RU 2131248 C1 RU2131248 C1 RU 2131248C1
Authority
RU
Russia
Prior art keywords
compound
alkyl
solution
glucose
phenyl
Prior art date
Application number
RU93045145A
Other languages
English (en)
Russian (ru)
Other versions
RU93045145A (ru
Inventor
Хеммерле Хорст
Шиндлер Петер
Утц Роланд
Риппель Роберт
Херлинг Андреас
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU93045145A publication Critical patent/RU93045145A/ru
Application granted granted Critical
Publication of RU2131248C1 publication Critical patent/RU2131248C1/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/383Cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018Esters of cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Pyridine Compounds (AREA)
RU93045145A 1992-09-09 1993-09-08 Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих RU2131248C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4230156 1992-09-09
DEP4230156.4 1992-09-09

Publications (2)

Publication Number Publication Date
RU93045145A RU93045145A (ru) 1996-06-20
RU2131248C1 true RU2131248C1 (ru) 1999-06-10

Family

ID=6467599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93045145A RU2131248C1 (ru) 1992-09-09 1993-09-08 Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих

Country Status (22)

Country Link
US (1) US5451573A (enExample)
EP (1) EP0587087B1 (enExample)
JP (1) JPH06211737A (enExample)
KR (1) KR100299205B1 (enExample)
CN (1) CN1042329C (enExample)
AT (1) ATE181237T1 (enExample)
AU (1) AU662836B2 (enExample)
CA (1) CA2105707A1 (enExample)
CZ (1) CZ284995B6 (enExample)
DE (1) DE59309649D1 (enExample)
DK (1) DK0587087T3 (enExample)
ES (1) ES2135429T3 (enExample)
FI (1) FI933902A7 (enExample)
GR (1) GR3030953T3 (enExample)
HU (1) HUT64843A (enExample)
IL (1) IL106935A (enExample)
NO (1) NO179671C (enExample)
PH (1) PH30278A (enExample)
PL (1) PL300328A1 (enExample)
RU (1) RU2131248C1 (enExample)
TW (1) TW255880B (enExample)
ZA (1) ZA936610B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252211C2 (ru) * 1999-10-25 2005-05-20 Авентис Фарма Дойчланд Гмбх Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
RU2291858C2 (ru) * 2001-05-25 2007-01-20 Санофи-Авентис Дойчланд Гмбх Замещенные амидом карбоновой кислоты производные фенилмочевины и их применение в качестве лекарственных средств

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4404848A1 (de) * 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
DE4408082A1 (de) * 1994-03-10 1995-09-14 Hoechst Ag Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
AR012449A1 (es) * 1997-04-18 2000-10-18 Hoechst Marion Roussell Deutschland Gmbh Kodaistatinas a, b, c y d, proceso para su produccion, y su uso.
JP4810558B2 (ja) * 1997-08-08 2011-11-09 江崎グリコ株式会社 リン酸化糖およびその製造方法
DE19740080A1 (de) * 1997-09-12 1999-03-18 Hoechst Marion Roussel De Gmbh Neue Phthalaldehyd-Derivate, Verfahren zu deren Herstellung und deren Verwendung
BR9912200A (pt) * 1998-06-24 2001-11-20 Aventis Pharma Gmbh Mumbaistatina, processo para sua produção e seuuso como produto farmacêutico
AU2005250487B2 (en) 2004-06-03 2012-03-29 Eisai R&D Management Co., Ltd Intermediates for the preparation of analogs of halichondrin B
CN101010276B (zh) * 2004-07-26 2011-01-12 中外制药株式会社 环己烷衍生物、其前体药物及其盐、以及含有它的糖尿病治疗药
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
JP6001857B2 (ja) 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体
US20100112098A1 (en) * 2008-10-31 2010-05-06 Naturex, S.A. Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
RU2710545C2 (ru) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, пригодные в получении аналогов халихондрина b
MX384292B (es) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
RU2739034C2 (ru) 2015-05-07 2020-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточное соединение и другие фрагменты, полезные в синтезе макролидов галихондринов
KR20180107243A (ko) 2016-02-12 2018-10-01 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린의 합성에서의 중간체 및 관련된 합성 방법
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
EP3737673B1 (en) 2018-01-03 2024-03-06 Eisai R&D Management Co., Ltd. Process for preparing halichondrin macrolides and analogs thereof by a prins reaction, and intermediates of this process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192555A (ja) * 1984-03-13 1985-10-01 Osaka Chem Lab 抗アレルギ−食品
JPS60243016A (ja) * 1984-05-17 1985-12-03 Tsumura Juntendo Inc 抗インフルエンザウイルス剤
EP0464858A1 (en) * 1984-05-23 1992-01-08 Green Cross Corporation A lipoxygenase inhibitor
DE3603576A1 (de) * 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Merck Index, Rahway, N.Y., 1989, p. 330 - 331, abstract N 2142. Haslam E. et al. The Shikimate Pathway. Part II. Conformational Analysis of (-)-Qunic Acid and Its Derivatives by proton Magnetic Resonance spectroscopy. Journal of The Chemical society. C(Organic), 1971, N 8, p. 1496 - 1500. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2252211C2 (ru) * 1999-10-25 2005-05-20 Авентис Фарма Дойчланд Гмбх Ароматические дикетопроизводные, способы получения и применение данных соединений в качестве фармацевтических средств
RU2291858C2 (ru) * 2001-05-25 2007-01-20 Санофи-Авентис Дойчланд Гмбх Замещенные амидом карбоновой кислоты производные фенилмочевины и их применение в качестве лекарственных средств

Also Published As

Publication number Publication date
NO179671B (no) 1996-08-19
CN1042329C (zh) 1999-03-03
TW255880B (enExample) 1995-09-01
KR940006580A (ko) 1994-04-25
NO179671C (no) 1996-11-27
DK0587087T3 (da) 1999-12-06
JPH06211737A (ja) 1994-08-02
GR3030953T3 (en) 1999-11-30
NO933201D0 (no) 1993-09-08
HUT64843A (en) 1994-03-28
HU9302527D0 (en) 1993-11-29
HK1011934A1 (en) 1999-07-23
IL106935A (en) 1997-07-13
CZ284995B6 (cs) 1999-04-14
CN1086806A (zh) 1994-05-18
CA2105707A1 (en) 1994-03-10
NO933201L (no) 1994-03-10
PL300328A1 (en) 1994-03-21
US5451573A (en) 1995-09-19
KR100299205B1 (ko) 2001-11-22
ZA936610B (en) 1994-03-28
EP0587087A1 (de) 1994-03-16
ATE181237T1 (de) 1999-07-15
FI933902A0 (fi) 1993-09-07
CZ186793A3 (en) 1994-03-16
PH30278A (en) 1997-02-20
AU662836B2 (en) 1995-09-14
EP0587087B1 (de) 1999-06-16
IL106935A0 (en) 1993-12-28
DE59309649D1 (de) 1999-07-22
AU4617093A (en) 1994-03-17
FI933902L (fi) 1994-03-10
FI933902A7 (fi) 1994-03-10
ES2135429T3 (es) 1999-11-01

Similar Documents

Publication Publication Date Title
RU2131248C1 (ru) Средство для ингибирования глюкозо-6-фосфатазной системы печени млекопитающих
US4686237A (en) Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
EP0235164B1 (en) Imidazole analogs of mevalonolactone and derivatives thereof
RU2126378C1 (ru) Замещенные производные циклогексана
DE69327796T2 (de) Antiproliferative substituierte 5-thiapyrimidinon- und 5-selenopyrimidinonverbindungen
JPH0440343B2 (enExample)
CS208129B2 (en) Method of preparation of the new spiro-oxazolidindions
EP0117228B1 (en) Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4992462A (en) Substituted pyrroles
US4732901A (en) Certain pyridyl, thienyl or furyl propenoic acids or esters having anti-inflammatory anti-allergic properties
AU3368099A (en) Antidiabetic agents
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
KR900009006B1 (ko) 메발로락톤의 동족체 및 그것의 유도체의 제조방법
CA2107150C (fr) Nouveaux derives chromeniques a chaine laterale trienique, leur procede de preparation et les compositions pharmaceutiques les renfermant
PL133220B1 (en) Method of obtaining new derivatives of oxazolidinodiene-2,4
US4588715A (en) Heptenoic acid derivatives
US4927851A (en) Analogs of mevalonolactone and derivatives thereof
US4751235A (en) Anti-atherosclerotic indolizine derivatives
EP0194226B1 (en) A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof
US4804679A (en) Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4289707A (en) Nitrogen heterocycles
PT87927B (pt) Processo para a preparacao de acidos 3,5-dihidroxi-hepta-6-enoicos substituidos por 7-(1h-pirrol-3-ilo), das suas correspondentes delta-lactonas e sais, e de composicoes farmaceuticas que os contem
US5075327A (en) Antipsoriatic agents
US4900829A (en) 2,4-disubstituted-5-cyano-1,6-dihydro-6-oxo-1-pyrimidineacetic acid aldose reductase inhibitors
US4378369A (en) Esters of 2,5-anhydro-D-mannitol